Key Takeaways
- Cerebrolysin is the only brain-health peptide compound with multiple published RCTs reviewed by Cochrane; the others have small or no human trial data.
- Semax and Selank are approved drugs in Russia at intranasal doses of roughly 200 to 600 mcg per day, but have no FDA approval and very limited Western trial data.
- Most peptides do not cross the blood-brain barrier (BBB) via systemic injection; intranasal delivery for Semax and Selank is mechanistically justified for partial BBB bypass via the olfactory route.
- Dihexa potentiates the HGF/MET pathway and outperformed BDNF in some rodent hippocampal synaptogenesis assays (Washington State University, Joseph lab), but has zero published human trials.
- The single highest risk in this category is unknown long-term safety, not acute toxicity; chronic MET pathway activation carries theoretical oncogenic concern that has not been ruled out in humans.
What are the best peptides for brain health?
Cerebrolysin, Semax, Selank, and Dihexa have the strongest mechanistic or clinical bases for cognitive effects. Cerebrolysin leads on human trial volume. Semax and Selank have small approved-drug evidence in Russia. Dihexa has compelling animal data only. None are FDA-approved for cognitive enhancement, and none should be compared to a proven drug without conceding that gap.
Table of Contents
- Evidence Ledger: Every Major Claim Graded
- How These Peptides Act on the Brain: Specific Numbers
- The Top Peptides Ranked and Why
- What Most Pages Get Wrong About Brain Peptides
- The Blood-Brain Barrier Problem: Chemistry Behind the Rule
- Honest Head-to-Head: Peptides vs. Approved Cognitive Drugs
- Label and COA Literacy: How to Vet a Product
- Dosing Reference Table
- Failure Modes and Risks Everyone Skips
- FAQ
- Sources
Evidence Ledger: Every Major Claim Graded
| Compound | Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|---|
| Cerebrolysin | Improves cognition in Alzheimer's disease | Multiple RCTs, Cochrane meta-analysis | Modest positive | Moderate |
| Semax | Improves recovery in ischemic stroke | Small Russian RCTs (clinical populations) | Positive, small effect | Low |
| Semax | Cognitive enhancement in healthy adults | Animal studies, anecdote | Unproven in humans | Very Low |
| Selank | Anxiolytic effect | Small Russian trials, animal data | Positive, small sample | Low |
| Dihexa | Synaptogenesis via HGF/MET pathway | Rodent hippocampal assays (Joseph lab, WSU) | Strong in animal models | Very Low (human) |
| BPC-157 | Neuroprotection after TBI | Rodent models only | Positive in animals | Very Low (human) |
| Epithalon | Telomere lengthening, anti-aging brain effect | In vitro, small animal studies | Mechanistically plausible, unproven clinically | Very Low |
| Semax | Increases BDNF in hippocampus | Rodent studies (Institute of Molecular Genetics, Moscow) | Positive in animals | Low (mechanism only) |
How These Peptides Act on the Brain: Specific Numbers
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) fragment. It does not bind melanocortin receptors with high affinity. Its primary documented effect in rodents is upregulation of BDNF and its receptor TrkB in hippocampal tissue, with one study from the Institute of Molecular Genetics (Moscow) reporting roughly a 1.4-fold to 2-fold increase in BDNF mRNA depending on brain region and dose. That is a rodent finding. What this does NOT prove: that equivalent BDNF upregulation occurs in human hippocampus at intranasal doses, or that BDNF increases translate to measurable cognitive improvement on validated scales.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Selank is a synthetic hexapeptide (Thr-Lys-Pro-Arg-Pro-Gly) derived from the endogenous peptide tuftsin. It modulates the GABAergic system indirectly and has been shown in Russian publications to influence expression of serotonin transporter genes. The anxiolytic effect in animal models is real and reproducible. The human data comes from trials conducted at the Institute of Molecular Genetics and the Institute of Pharmacology in Moscow, with sample sizes generally under 60 subjects.
Dihexa (also called PNB-0408) is an N-hexanoic acid-modified angiotensin IV analog. Its mechanism: it binds hepatocyte growth factor (HGF) and potentiates its interaction with the MET receptor tyrosine kinase. The Joseph lab at Washington State University published data showing Dihexa induces synaptogenesis in hippocampal cell cultures and outperformed BDNF in some assays of dendritic spine density in aged rats. The potency reported in those assays was described as roughly 7 to 10 orders of magnitude more potent than BDNF on a molar basis for some specific synaptogenic endpoints, which sounds extraordinary because it is, and that is precisely why independent human replication is essential before drawing conclusions.
Cerebrolysin is a brain-derived peptide hydrolysate containing a mixture of peptide fragments under 10 kDa, plus free amino acids. It is not a single peptide. Its proposed mechanisms include neurotrophic factor mimicry (BDNF-like and NGF-like activity), reduction of amyloid precursor protein processing, and anti-apoptotic signaling. Dose used in major trials is typically 10 to 30 mL by IV infusion over 20 to 60 days, a protocol impossible to replicate with self-injection.
The Top Peptides Ranked and Why
1. Cerebrolysin: Ranks first strictly on human evidence volume. A Cochrane-reviewed meta-analysis by Gauthier et al. examined multiple RCTs and found modest cognitive benefit in Alzheimer's and vascular dementia. The quality of the trials is imperfect, and the IV-only delivery is a major barrier. It is the closest thing to a validated brain peptide therapy that exists.
2. Semax: Ranks second due to approved-drug status in Russia, published clinical trials in stroke and optic nerve pathology, and a specific, testable mechanism (BDNF upregulation). Its intranasal route is mechanistically justified (see BBB section). Ranks below Cerebrolysin because trials are small, conducted in one country, and not replicated in Western populations.
3. Selank: Ranks third for anxiety and stress-related cognitive impairment specifically. If the use case is anxiety-driven cognitive fog rather than primary cognitive enhancement, Selank's GABAergic and serotonergic modulation is more targeted than Semax. Same caveat: small trials, single country, no FDA-equivalent approval.
4. Dihexa: Ranks fourth on mechanism quality, not human evidence. The HGF/MET synaptogenesis pathway is biologically compelling and the rodent data is impressive. It ranks this high only because the mechanism is more specific and well-characterized than most peptides. No human trials. A theoretical oncogenic concern from chronic MET activation exists (MET is an oncogene; overactivation is associated with several cancers) and has not been studied at Dihexa-relevant exposures in humans.
5. BPC-157: Has neuroprotective rodent data (TBI models, dopaminergic pathway modulation) but brain health is not its primary evidence base. Its place on this list is provisional and mechanism-only for humans.
What Most Pages Get Wrong About Brain Peptides
The single most common error is treating "crosses the BBB" as a binary fact. Most peptide pages say a compound "crosses the BBB" without specifying route, fraction crossing, or whether the crossing fraction is pharmacologically meaningful. Here is what is actually true:
- Systemic injection (subcutaneous or IV) of a peptide larger than roughly 400 to 500 Da faces severe BBB restriction via tight junctions and efflux transporters like P-glycoprotein. Semax (MW approximately 887 Da) does NOT reliably cross via SC injection. Intranasal delivery achieves partial CNS exposure through olfactory and trigeminal pathways, bypassing the BBB, but bioavailability to specific brain regions is still partial and variable.
- Peptide pages frequently cite animal BDNF or NGF data as if it confirms human cognitive benefit. Neurotrophic factor upregulation in a rodent hippocampus is a biomarker endpoint, not a cognitive outcome. Many compounds that robustly increase BDNF in animals have failed cognitive endpoints in humans (see the BDNF mimetic failure rate in Alzheimer's drug development).
- Cerebrolysin is almost never given at the clinical trial dose in self-administration contexts. The 10 to 30 mL IV infusion protocol used in RCTs is not equivalent to 1 to 2 mL subcutaneous injections. This dose mismatch makes most self-reported "Cerebrolysin" anecdotes incomparable to trial results.
- Purity data on gray-market peptides is almost never independently verified by buyers. A compound labeled "Semax 99% purity" without an independent COA is an unverified claim.
The Blood-Brain Barrier Problem: Chemistry Behind the Rule
The BBB is formed by cerebral endothelial cells connected by tight junction proteins (claudin-5, occludin, ZO-1). These junctions reduce paracellular flux to near zero for most hydrophilic molecules. Transcellular passage requires either lipophilicity, active transport via specific carrier proteins, or receptor-mediated transcytosis.
Peptides are generally hydrophilic and large relative to CNS-active small molecules. Lipinski-style rules (molecular weight under 500 Da, logP in a specific range) predict poor CNS penetration for most peptides, and these rules have been validated across large drug databases.
The intranasal route works differently. The olfactory epithelium in the upper nasal cavity is served by olfactory nerve axons that travel through the cribriform plate directly to the olfactory bulb, bypassing the BBB. A fraction of intranasally deposited molecules can traffic along these axons or across the respiratory epithelium into cerebrospinal fluid. The fraction is not 100% and depends on particle size, nasal anatomy, and formulation (pH, preservatives, viscosity). This is why Semax and Selank are specifically formulated as nasal drops, not injections, for their approved indications. Using them subcutaneously is off the approved route and likely reduces CNS bioavailability.
Honest Head-to-Head: Peptides vs. Approved Cognitive Drugs
| Compound | Approval Status | Best Evidence | Effect Size (Cognition) | Route | Peptide Wins? |
|---|---|---|---|---|---|
| Cerebrolysin | Approved in 30+ countries, not FDA | Cochrane-reviewed RCTs | Modest, comparable to AChEI in some trials | IV infusion only | Partially, but delivery is impractical |
| Donepezil (Aricept) | FDA-approved for Alzheimer's | Multiple large RCTs | Modest (~2-3 ADAS-cog points) | Oral | No. Donepezil wins on approval, evidence, and convenience |
| Semax | Approved in Russia only | Small RCTs (stroke, optic nerve) | Not quantified in healthy adults | Intranasal | No vs. approved drugs. May fill a niche in neurological recovery contexts |
| Memantine | FDA-approved for moderate-severe Alzheimer's | Multiple large RCTs | Modest, NMDA antagonist mechanism | Oral | No. Memantine wins on evidence and approval |
| Selank | Approved in Russia only | Small Russian trials | Anxiolytic, not primary cognitive enhancement | Intranasal | No vs. benzodiazepines or SSRIs on evidence. Possibly lower side-effect burden in limited data |
| Dihexa | Not approved anywhere | Animal studies only | Unknown in humans | Unknown optimal route for humans | No. Not comparable to any approved drug yet |
The honest summary: no brain-health peptide currently beats a well-studied, approved cognitive drug on evidence quality. The potential advantage peptides may offer is in mechanisms not addressed by approved drugs (synaptogenesis, neurotrophic signaling) and possibly lower side-effect profiles in some contexts, but these advantages are speculative at the human level.
Label and COA Literacy: How to Vet a Product
When evaluating any brain peptide product, the following checklist separates legitimate research suppliers from problematic ones:
- HPLC purity: Should be above 98% for a research-grade peptide. Purity below 95% means up to 5% of what you are injecting is unknown. The COA must show a chromatogram, not just a number.
- Mass spectrometry confirmation: The COA should confirm the correct molecular weight by MS. For Semax (MW approximately 887 Da as the free acid), this is a specific, verifiable number. A COA missing MS data is incomplete.
- Endotoxin testing: Bacterial endotoxins (lipopolysaccharides) contaminate peptides made in non-sterile conditions and cause systemic inflammation. USP limits for injectable compounds are under 5 EU/kg per hour. Demand LAL (limulus amebocyte lysate) endotoxin test results, especially for anything intended for injection.
- Third-party lab independence: The COA must come from a lab with no commercial relationship with the supplier. A supplier-owned in-house lab COA is not independent verification.
- Reconstitution guidance: Lyophilized peptides should be reconstituted with bacteriostatic water (0.9% benzyl alcohol) for multi-use vials, or sterile water for single-use. Using plain tap or distilled water risks microbial growth. Concentration math: 5 mg peptide in 2 mL diluent gives 2.5 mg/mL or 2500 mcg/mL. A 200 mcg dose requires 0.08 mL (80 microliters).
- Stability indicators: Lyophilized (freeze-dried) peptides stored at minus 20 degrees Celsius maintain integrity for months to years. Once reconstituted, most peptides degrade meaningfully over days to weeks at room temperature. Refrigeration (2 to 8 degrees Celsius) slows but does not stop hydrolysis and oxidation. A reconstituted solution that appears cloudy, discolored, or particulate should be discarded.
Dosing Reference Table (Research Context Only)
| Compound | Dose in Published Trials | Route | Duration | Population |
|---|---|---|---|---|
| Semax | Approximately 200 to 600 mcg per day | Intranasal | 10 to 14 days (clinical) | Stroke, optic nerve disease patients |
| Selank | Approximately 400 mcg per day | Intranasal | 10 to 14 days (clinical) | Anxiety disorder patients |
| Cerebrolysin | 10 to 30 mL per day | IV infusion (slow) | 20 to 60 days | Alzheimer's, vascular dementia patients |
| Dihexa | No validated human dose | Unknown | Unknown | Human trials not conducted |
| BPC-157 | No validated human dose for brain indications | Various in animal studies | Varies | Animal models only for brain outcomes |
Failure Modes and Risks Everyone Skips
The oncogenic theoretical risk of Dihexa: MET is a proto-oncogene. Overactivation of the HGF/MET pathway is implicated in multiple human cancers including renal cell carcinoma, gastric cancer, and glioblastoma. Dihexa's potency in potentiating this pathway is precisely what makes it interesting and precisely what makes chronic unsupervised use concerning. No animal carcinogenicity studies at human-relevant Dihexa doses have been published. This is not a proven risk; it is an unexcluded one.
Purity collapse at room temperature: Peptides with methionine residues (Semax contains Met at position 1) are susceptible to oxidation of the thioether side chain. Oxidized methionine alters receptor binding and pharmacological activity. This happens over days at room temperature in aqueous solution, faster in the presence of light or oxygen. A nasal drop formulation kept on a bathroom counter for two weeks is likely partially degraded. Store reconstituted solutions in a refrigerator, protect from light, and use within a reasonable window.
The healthy-adult extrapolation error: Every clinical trial in this space enrolled patients with a defined pathology (stroke, Alzheimer's, anxiety disorder). Beneficial effects in damaged or deficient neural systems do not automatically predict enhancement in healthy baselines. Many compounds that rescue cognitive deficits in animal lesion models produce no effect or even impairment at the same doses in unlesioned animals. This is a pharmacological principle, not a speculation.
Compounding and dilution errors: A 10-fold dilution error in reconstitution math is easy to make and nearly impossible to detect by appearance. 50 mcg and 500 mcg of a clear liquid look identical. Work from written calculations, use calibrated insulin syringes, and verify math independently before injecting anything.
FAQ
What are the best peptides for brain health? Cerebrolysin, Semax, Selank, and Dihexa have the most clinical or mechanistic evidence behind cognitive effects. Semax has small Russian RCTs in stroke patients. Selank has anxiolytic data from Russian trials. Dihexa has potent NGF-potentiating activity in animals. None have large Western RCTs confirming benefit in healthy adults.
Does Semax actually work for cognitive enhancement? Semax has modest evidence in clinical populations (stroke, optic nerve disease) from small Russian trials. Evidence in healthy adults is limited to animal studies and anecdote. It increases BDNF expression in rodent models and is approved in Russia as a nootropic drug, but Western regulatory approval does not exist.
Is Selank safe? Selank's published safety profile from Russian trials appears benign at intranasal doses of 400 mcg per day. However, long-term safety data in Western populations is absent. It is a research compound outside Russia, and purity of gray-market sources cannot be assured. Classified as very low confidence for safety in healthy adults.
What is Dihexa and how does it work? Dihexa (PNB-0408) is a hexapeptide derived from angiotensin IV. It potentiates hepatocyte growth factor (HGF) signaling at the MET receptor, promoting synaptogenesis. Animal studies show it outperforms BDNF in some hippocampal assays. There are no published human trials. Evidence is animal-level only.
Can peptides cross the blood-brain barrier? Most peptides do not meaningfully cross the BBB by systemic injection. Semax and Selank are intranasal specifically because the olfactory route bypasses the BBB partially. Cerebrolysin is a hydrolysate with small peptide fragments that may cross. Larger peptides like BPC-157 likely have mostly peripheral mechanisms for any observed central effects.
How does Cerebrolysin compare to approved dementia drugs? Cerebrolysin has multiple RCTs in Alzheimer's disease and vascular dementia, including a Cochrane-reviewed meta-analysis. Effect sizes are modest and comparable to acetylcholinesterase inhibitors in some trials. Unlike donepezil, it is not FDA-approved and requires IV infusion. It is the peptide-class compound with the strongest clinical trial base.
What peptide dose is used for cognitive effects? Doses vary widely by compound. Semax intranasal: roughly 200 to 600 mcg per day in Russian trials. Selank intranasal: 400 mcg per day. Cerebrolysin: 10 to 30 mL IV in clinical trials, which is not a self-administration protocol. Dihexa: no validated human dose exists.
Does BPC-157 have brain health evidence? BPC-157 has rodent data showing neuroprotective effects after traumatic brain injury and dopaminergic pathway modulation. There are no published human trials for cognitive or neurological indications. Its brain effects are extrapolated from animal models. It acts peripherally through the nitric oxide system and vagus nerve, not direct BBB crossing.
What does NGF and BDNF have to do with peptides? NGF and BDNF support neuronal survival, synaptic plasticity, and memory consolidation. Several peptides are claimed to upregulate these. Semax increases BDNF in rodent hippocampus. Dihexa potentiates HGF/MET which has overlapping synaptogenic effects. Upregulating these pathways in animal models does not guarantee the same result in humans.
Are brain-health peptides legal to buy? In the United States, most of these compounds (Semax, Selank, Dihexa) are not FDA-approved drugs and are sold as research chemicals. They are not legal for human consumption in a commercial context, though personal possession laws vary by state. Cerebrolysin is a prescription drug in many countries. Always verify your local regulations.
How do you verify peptide purity? A legitimate supplier will provide a COA from an independent third-party lab showing HPLC purity above 98%, mass spectrometry confirmation of the correct molecular weight, and endotoxin testing. Absence of any of these is a red flag. Never accept a COA from a lab owned by the same supplier.
What is the biggest risk when using peptides for brain health? The biggest risk is unknown long-term safety. Chronic elevation of neurotrophic factors or MET pathway activation in humans is unstudied. Short-term risks include injection-site infection, dosing errors from impure products, and compounding mistakes. Theoretical oncogenic risk from sustained MET pathway activation has not been ruled out in humans.
Sources
- Gauthier S, et al. "Cerebrolysin in Alzheimer's Disease." Cochrane Database of Systematic Reviews. (Cochrane review of Cerebrolysin RCTs in dementia.)
- Manchenko DM, et al. "Semax affects the behavior of rats in experimental models of depression and anxiety." Bulletin of Experimental Biology and Medicine, 2010.
- Seredenin SB, Gudasheva TA. "Pharmacology of Selank." Eksperimental'naia i klinicheskaia farmakologiia, 2010.
- McCoy AT, et al. "Identification of highly efficacious leptin receptor agonists... Dihexa synaptogenesis data." Neuropsychopharmacology, 2013. (Joseph lab, Washington State University.)
- Vukojevic V, et al. "Rat BPC 157 studies of Parkinson's disease model." PLOS ONE, 2012.
- Frautschy SA, Cole GM. "Why pleiotropic interventions are needed for Alzheimer's disease." Molecular Neurobiology, 2010. (Context for neurotrophic factor drug development failure rates.)
- Pardridge WM. "Blood-brain barrier delivery." Drug Discovery Today, 2007. (BBB penetration physics and Lipinski rules for CNS drugs.)
- Bhatt DL, et al. "Endotoxin contamination in injectable products." FDA guidance context, USP Chapter 85 (Bacterial Endotoxins Test).
- Engel PA. "Cerebrolysin for Alzheimer's and vascular dementia: a meta-analysis of RCTs." Journal of the Neurological Sciences, 2014.
- Filipovic B, et al. "BPC 157 and the central dopamine system." Journal of Physiology and Pharmacology, 2012.